Biomarin Pharmaceutical

Yahoo Finance • 5 days ago

BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN): A Prime Value Investment with Strong Fundamentals and Growth Potential

Value investing focuses on finding stocks priced below their true value while showing good financial strength, earnings potential, and room for expansion. The "Decent Value" screen selects companies with a valuation score above 7, meaning... Full story

Yahoo Finance • 6 days ago

Leerink Partners Reiterates a Buy Rating on BioMarin Pharmaceutical (BMRN), Sets a PT of $105

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the top most undervalued biotech stocks to buy now. Analyst Joseph Schwartz from Leerink Partners reiterated a Buy rating on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) on August 6, keepi... Full story

Yahoo Finance • 13 days ago

BioMarin stock rating reiterated at Overweight by Cantor Fitzgerald

Investing.com - BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), currently trading at $63.50 and rated "Great" by InvestingPro’s comprehensive health score system, received a reiterated Overweight rating and $90.00 price target from Cantor Fitz... Full story

Yahoo Finance • 13 days ago

BioMarin stock rating reiterated at Buy by Stifel on strong Q2 results

Investing.com - Stifel has reiterated its Buy rating and $91.00 price target on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) following the company’s second-quarter financial results that exceeded analyst expectations. According to InvestingP... Full story

Yahoo Finance • 13 days ago

BioMarin raises 2025 full-year guidance with $3.125B revenue target and advances BMN 333

Earnings Call Insights: BioMarin Pharmaceutical Inc. (BMRN) Q2 2025 MANAGEMENT VIEW * Alexander Hardy, President and CEO, reported "strong growth, exciting progress across the pipeline and delivery of our business development strategy.... Full story

Yahoo Finance • 14 days ago

BioMarin shares gain as Q2 earnings smash estimates

Investing.com -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) shares jumped 4.5% after the biotech company reported second-quarter earnings that significantly exceeded analyst expectations, driven by strong sales of its rare disease treatmen... Full story

Yahoo Finance • last month

Nasdaq Bull Market: 3 Historically Cheap Stocks That Can Easily Double Your Money

Key Points The Nasdaq Composite has been on a roller-coaster ride in 2025, with the index enduring a short-lived bear market that's now given way to a new bull market. Although the stock market is historically pricey, pockets of value ca... Full story

Yahoo Finance • last month

BioMarin Pharmaceutical (BMRN) Finalizes the Acquisition of Inozyme Pharma

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the 10 Best Growth Stocks to Buy With Huge Upside Potential.On July 1, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced the finalization of its acquisition of Inozyme Pharma, Inc. T... Full story

Yahoo Finance • 2 months ago

BioMarin completes $270 million acquisition of Inozyme Pharma

SAN RAFAEL, Calif. - BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), a biotechnology company with a market capitalization of $10.5 billion and a perfect Piotroski Score of 9 according to InvestingPro, has completed its acquisition of Inozyme P... Full story

Yahoo Finance • 2 months ago

BioMarin's hemophilia gene therapy shows sustained results at 5 years

WASHINGTON, D.C. - BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), a $10.37 billion biotech company with an impressive 81% gross profit margin, announced Tuesday that its hemophilia A gene therapy ROCTAVIAN maintained efficacy and safety five... Full story

Yahoo Finance • 2 months ago

BioMarin's SWOT analysis: stock growth potential amid rare disease focus

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), a biotechnology company specializing in innovative therapies for rare diseases, has been garnering significant attention from analysts due to its strong financial performance and promising produc... Full story

Yahoo Finance • 3 months ago

Leerink bullish on BioMarin following Inozyme deal, expects additional BD

Leerink analyst Joseph Schwartz notes BioMarin (BMRN) believes INZ-701 could be a $400M-$600M opportunity at peak, making it a nice addition to the company’s ERT portfolio; this is likely the first business development deal in 2025. Before... Full story

Yahoo Finance • 3 months ago

BioMarin Pharmaceutical Inc. (BMRN): Among Billionaire Paul Singer’s Stock Picks with Huge Upside Potential

We recently published a list of Billionaire Paul Singer’s 10 Stock Picks with Huge Upside Potential. In this article, we are going to take a look at where BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) stands against other stock picks with hug... Full story

Yahoo Finance • 4 months ago

What To Expect From BioMarin Pharmaceutical’s (BMRN) Q1 Earnings

Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) will be reporting earnings tomorrow after the bell. Here’s what to look for. BioMarin Pharmaceutical beat analysts’ revenue expectations by 4.8% last quarter, reporting revenues of $74... Full story

Yahoo Finance • 4 months ago

BioMarin Pharmaceutical Inc. (BMRN): Among Billionaire Andreas Halvorsen’s Stock Picks With Huge Upside Potential

We recently published a list of Billionaire Andreas Halvorsen’s 10 Stock Picks With Huge Upside Potential. In this article, we are going to take a look at where BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) stands against other billionaire An... Full story

Yahoo Finance • 5 months ago

BioMarin Presents New Data Demonstrating Favorable Safety and Strong Adherence in Real-World Clinical Practice with VOXZOGO® (vosoritide) in Children Under 3 with Achondroplasia at 2025 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting

New data also to be presented for PALYNZIQ® (pegvaliaise-pqpz), reinforcing its value in sustaining blood Phe level reduction and improving health-related quality of life for adults with phenylketonuria SAN RAFAEL, Calif., March 20, 2025... Full story

Yahoo Finance • 6 months ago

BioMarin Pharmaceutical Full Year 2024 Earnings: Beats Expectations

BioMarin Pharmaceutical (NASDAQ:BMRN) Full Year 2024 Results Key Financial Results Revenue: US$2.85b (up 18% from FY 2023). Net income: US$426.9m (up 155% from FY 2023). Profit margin: 15% (up from 6.9% in FY 2023). The increase in margi... Full story

Yahoo Finance • 7 months ago

Is BioMarin Pharmaceutical (BMRN) the Best Depressed Stock to Invest in Now?

We recently published a list of 12 Best Depressed Stocks to Invest in Now. In this article, we are going to take a look at where BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) stands against other best depressed stocks to invest in now. The U... Full story

Yahoo Finance • last year

U.S. Food and Drug Administration Approves BioMarin's BRINEURA® (cerliponase alfa) for Children Under 3 Years with CLN2 Disease

Now Approved for Children of All Ages with CLN2 Batten Disease, Regardless of Whether They Yet Show Symptoms SAN RAFAEL, Calif., July 24, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the U.S. Food... Full story

Yahoo Finance • last year

4 Dominant Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market

It's been a wild ride for investors since this decade began. Through each of the first four years, all three major stock indexes have traded off bear and bull markets, with the growth-fueled Nasdaq Composite(NASDAQINDEX: ^IXIC) enduring th... Full story